1. Scrip
  2. >>Focus On Asia

China At ASCO: Biotech Pharma, Akeso, Chongqing Precision Showcase Promising Data

Oncology Rise Continues

 
• By Dexter Jie Yan

EGFR-targeting antibody, anti-PD-1/CTLA4 bispecific antibody and CD19-targeting CAR-T therapy from emerging Chinese oncology companies shine at one of ASCO’s most-watched sessions.

symposium
Notable data readouts from three Chinese biotechs catch attention at ASCO • Source: Shutterstock

Three Chinese biotechs - BIOTECH PHARMA Co Ltd, Akeso Inc. and Chongqing Precision - have made their debuts in the clinical science symposium of the annual American Society of Clinical Oncology (ASCO) meeting, taking place over 3-7 June.

The presented data served to showcase potential therapeutic advancements, including promising breakthroughs for pancreatic, cervical and hematological malignancies.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia